THE ECHO BLOG
FACES OF ECHO: RUTH KASSEL
POSTED SEPTEMBER 30 AT 9:19 AM
By Erin Murphy/ ECHO
our Genes? Who Manages our Food?
Thursday, January 20, 2011, 6:30 - 8:30 p.m. ECHO Lake
Aquarium and Science Center/Leahy Center for Lake Champlain,
Burlington Waterfront, Burlington, VT
A mind expanding thought provoking evening for adults,
exploring challenging topics with industry experts.
Could genetic engineering of our food supply have a place in
alleviating world hunger? Disease? Should one person's right to
privacy about genomic information ever outweigh another person's
right to access medical treatment? How do we decide whose rights
will prevail? Join us in conversation with David Yandell,
D.Sc. Professor Pathology and Medicine, UVM College of Medicine.
Free event for 21+ with cash bar and themed drink; FREE hors
d'oeuvres sponsored by VT Sigma Xi, Scientific Research
A bio about David Yandell:
Dr. Yandell is a human geneticist and Professor of
Pathology and Medicine at the UVM College of Medicine.
He is the scientific Director of the UVM/FAHC Molecular
Diagnostics Laboratory, and was the director of the
Vermont Cancer Center from 1995-2006. He was the
principal investigator and project director of the
Community Genetics and Ethics Project, a statewide
project funded by the National Human Genome Research
Institute to disseminate information to Vermonters on
the ethical impact of new genetic technologies. On
coming to UVM in 1993, Dr. Yandell helped establish and
directed the Familial Cancer Program and also helped
found and co-Directed the Vermont Human Genetics
Initiative, a UVM-based program from which the NHGRI-funded
Community Genetics and Ethics Project developed in 1998.
Dr. Yandell has a longstanding professional interest
in human genetic diseases, particularly familial cancer
syndromes, and in development and application of
DNA-based clinical diagnostic testing for genetic
diseases. His research career has focused on the cloning
or characterization of genes related to cancer
predisposition including the human retinoblastoma gene,
the genetics of retinoblastoma and other
cancer-predisposition syndromes, the molecular pathology
of cancer, and development of cost-effective tools for
genetic testing. Dr. Yandell has chaired numerous
national symposia and workshops on subjects related to
cancer and molecular diagnostics, serves as a regular
reviewer for various granting agencies and scientific
journals, and is the author of more than 100 research
articles and chapters. He is also an inventor on a
number of patents related to human genes and diagnostic
technologies. Prior to coming to the University of
Vermont in 1993, Dr. Yandell was a faculty member at the
Harvard Medical School and the Harvard School of Public
Health for 7 years. Dr. Yandell is a native Vermonter
who now lives in Williston.
Some questions David will be considering in his
- What have we learned since the sequencing of the
human genome 10 years ago?
- How good is today’s technology and how will this
change our lives
- What’s coming down the road? Do you really want
- Who should own your genes? Are gene patents a
'necessary evil' that reward discovery, or should
the human genome be off limits?
- Could genetic engineering of our food supply
have a place in alleviating world hunger? Disease?
- Should one person's right to privacy about
genomic information ever outweigh another person's
right to access medical treatment? How do we decide
whose rights will prevail?
Links on the topic:
To treat two rare disorders, this firm uses defanged HIV
virus to get ‘corrected’ genetic material into cells, By
Karen Weintraub , Globe Correspondent / August 2, 2010
Deadly Viruses Have Been Part of Us for Millions of Years
Who Am I? This website address questions such as: What
happened after the human genome project? What was the human
genome project? What did the human genome project find?
UVM page on David Yandell. Includes publications, education,
and awards and honors
Feds’ Transgenic-Salmon Review Ignores Big Picture, By
Brandon Keim , November 18, 2010
When the Food and Drug Administration announces the fate of
the AquAdvantage salmon, the first genetically modified (GM)
animal ever considered for commercial consumption, they may
have considered only a fraction of their decision’s
generic NHGRI educational link, although somewhat dated,
it's good for folks who need a broader look.
Scientific American article: Revolution Postponed: Why the
Human Genome Project Has Been Disappointing
Cafe Scientifique questions or topic suggestions?
contact Linda Bowden at
Our next Cafe Scientifique will be Thursday, March 3,
Scientifique is sponsored by: